Back to today’s briefing

Story perspectives

UK Approves Oral Wegovy; Novo Cuts Prices, Forecasts Revenue Fall

6/27/2026

35 7 Full Breakdown

Summary

Story summary

UK regulator MHRA approved the oral Wegovy pill, the first GLP-1 weight-loss tablet in the United Kingdom.
The OASIS 4 trial reported weight loss in the low-to-high teens versus low single-digit loss for placebo.
A U.S. agreement capped therapy prices at $245, prompting Novo Nordisk to cut Wegovy and Ozempic prices from January 2027.
Management forecast a 4%-12% decline in currency-adjusted revenue and operating profit for 2026.

1 of 1

Story summary

UK regulator MHRA approved the oral Wegovy pill, the first GLP-1 weight-loss tablet in the United Kingdom.
The OASIS 4 trial reported weight loss in the low-to-high teens versus low single-digit loss for placebo.
A U.S. agreement capped therapy prices at $245, prompting Novo Nordisk to cut Wegovy and Ozempic prices from January 2027.
Management forecast a 4%-12% decline in currency-adjusted revenue and operating profit for 2026.